Sectoral Asset Management

SKILLFUL INVESTMENT IN LATE-STAGE COMPANIES ALLOWS NEMO TO CAPTURE EXCEPTIONAL VALUE.

Launched at the end of 2007, the New Emerging Medical Opportunities (NEMO) strategy is focused on companies involved in the development of new pharmaceuticals, medical technology devices and related products to serve the global healthcare market

Follow Our Latest News & Publications

MIACH ORTHOPAEDICS SECURES $40 MILLION FINANCING

AMOLYT PHARMA ANNOUNCES RESEARCH AGREEMENT AND LICENSING OPTION WITH XOMA

LARGE-SCALE, PEER-REVIEWED STUDY QUANTIFIES MULTIPLE DEVASTATING PATIENT HARMS ASSOCIATED WITH BLOOD CULTURE CONTAMINATION AND MOST SIGNIFICANTLY, A 74% INCREASE IN RISK OF IN-HOSPITAL PATIENT MORTALITY

12-MONTH CLINICAL RESULTS OF A NOVEL MICRO-INTERVENTIONAL BIO-STENTING PROCEDURE PUBLISHED IN THE BRITISH JOURNAL OF OPHTHALMOLOGY

AMOLYT PHARMA ANNOUNCES $138 MILLION SERIES C FINANCING LED BY SOFINNOVA PARTNERS AND CO-LED BY INTERMEDIATE CAPITAL GROUP

2022 Q4: RISE OF THE ADCS: THE EMERGING ROLE OF ANTIBODY-DRUG CONJUGATES IN CANCER TREATMENT

TURNSTONE BIOLOGICS ENTERS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE NATIONAL CANCER INSTITUTE TO STUDY TIL THERAPY IN COMBINATION WITH VIRAL IMMUNOTHERAPY

CONTENERE LA CRESCITA DELLA CURVA DEI COSTI DELL'HEALTHCARE

LET’S STAY IN TOUCH

1010 Sherbrooke St West, Suite 1610 Montreal, QC H3A 2R7 Canada Tel : +1 514 849 8777 Fax : +1 514 849 6777 7 rue du Mont Blanc Tel : +41 22 316 66 37 Fax : +41 22 316 66 31 Unit 2302, 23/F, Golden Center 188 Des Voeux Road Central, Hong Kong Tel : +852 8100 8732 Fax : +852 8100 1090